ZEB1 and neoplasm: Furthermore, although there is pre-clinical evidence that ZEB1 induces PD-L1 expression in tumor cells by relieving miRNA-200 suppression (thus suggesting that the EMT phenotype may respond to checkpoint inhibitors) [25], the lack of PD-L1-positive DSRCT cells suggests that this is unlikely to have any therapeutic significance, although it goes without saying that the data must be confirmed in large case series.